Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ellipticine (Elliptisine) is a potent antineoplastic agent exhibiting multiple mechanisms of action, IC50 of 0.67±0.06, 1.25±0.13, 1.25±0.13, 0.67±0.06, 0.27±0.02, 0.49±0.04, 0.44±0.03, and 1.48±0.62 μM for Leukemia HL-60, Breast adenocarcinoma MCF-7, Breast adenocarcinoma MCF-7, Leukemia HL-60, Neuroblastoma IMR-32, Neuroblastoma UKF-NB-4, Neuroblastoma UKF-NB-3, and Glioblastoma U87 mg cell, respectively.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 11,000 | |||
10 mg | 在庫あり | ¥ 16,500 | |||
25 mg | 在庫あり | ¥ 27,500 | |||
50 mg | 在庫あり | ¥ 40,500 | |||
100 mg | 在庫あり | ¥ 60,500 | |||
500 mg | 在庫あり | ¥ 147,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 11,500 |
説明 | Ellipticine (Elliptisine) is a potent antineoplastic agent exhibiting multiple mechanisms of action, IC50 of 0.67±0.06, 1.25±0.13, 1.25±0.13, 0.67±0.06, 0.27±0.02, 0.49±0.04, 0.44±0.03, and 1.48±0.62 μM for Leukemia HL-60, Breast adenocarcinoma MCF-7, Breast adenocarcinoma MCF-7, Leukemia HL-60, Neuroblastoma IMR-32, Neuroblastoma UKF-NB-4, Neuroblastoma UKF-NB-3, and Glioblastoma U87 mg cell, respectively. |
ターゲット&IC50 | IMR-32 cells:0.27±0.02μM, MCF-7 cells:1.25±0.13μM, UKF-NB-3 cells:0.44±0.03μM , HL-60 cells (leukemia):0.67±0.06μM, UKF-NB-4 cells:0.49±0.04μM, U-87 MG cells (Glioblastoma):1.48±0.62 μM |
別名 | NSC 71795, Elliptisine |
分子量 | 246.31 |
分子式 | C17H14N2 |
CAS No. | 519-23-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5 mg/mL (20.3 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ellipticine 519-23-3 DNA Damage/DNA Repair Topoisomerase NSC71795 Inhibitor NSC 71795 NSC-71795 Elliptisine inhibit inhibitor